The company has reported a net income of $431,000, or $0.01 per diluted share, compared to net income of $199.81m or $0.29 loss per diluted share, for the same period last year.
The company’s operating income was $1.32m, as compared to $22.26m for the same period prior year.
Enzon chairman of the board Alex Denner said they have had a productive start to 2011, as they completed their transformation to an R&D organization and successfully executed their strategy focused on the development of their oncology pipeline.
"Our clinical progress, reflected in the initiation of our Phase I trial for our Androgen Receptor antagonist and the presentation of encouraging data from our portfolio of mRNA antagonists, was complemented by our continued commitment to return value to our shareholders through our share repurchase program," Denner said.